In summary, targeting the SIRT6-PPARα-mediated lipolysis and the TGF-β/SIRT7/FOXO4-regulated glutamine metabolic pathway may be a potential strategy for the treatment of pulmonary fibrosis and related diseases. This evidence concerns the gene FOXO4 and pulmonary fibrosis.